Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

A Systematic Review of the Bimanual Examination as a Test for Ovarian Cancer

(2015) Mark H. Ebell et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside

(2015) Laura Vela et al.   CURRENT OPINION IN PHARMACOLOGY

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma

(2015) Justus Lieber et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737

(2015) Danielle S. Potter et al.   NEOPLASIA

Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs

(2014) Phyllis N. Butow et al.   GYNECOLOGIC ONCOLOGY

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells

(2014) Bin Wang et al.   Molecular Cancer

Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity

(2014) D Schmid et al.   Cell Death & Disease

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Bcl-2 antagonists: a proof of concept for CLL therapy

(2013) Kumudha Balakrishnan et al.   INVESTIGATIONAL NEW DRUGS

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function

(2012) S. M. Schoenwaelder et al.   BLOOD

Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis

(2012) A. Bagnato et al.   Current Oncology

Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells

(2012) Vasileios A. Stamelos et al.   GYNECOLOGIC ONCOLOGY

The secret life of Bcl-2: Apoptosis-independent inhibition of DNA repair by Bcl-2 family members

(2012) Corentin Laulier et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

BH3 mimetics activate multiple pro-autophagic pathways

(2011) S A Malik et al.   ONCOGENE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance

(2010) John O. Schorge et al.   GYNECOLOGIC ONCOLOGY

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

Control of mitochondrial apoptosis by the Bcl-2 family

(2009) J. K. Brunelle et al.   JOURNAL OF CELL SCIENCE

Drug interactions and the evolution of antibiotic resistance

(2009) Pamela J. Yeh et al.   NATURE REVIEWS MICROBIOLOGY